期刊
PHARMACOGENOMICS
卷 16, 期 1, 页码 45-60出版社
FUTURE MEDICINE LTD
DOI: 10.2217/PGS.14.152
关键词
glinides; mitiglinide; nateglinide; pharmacogenomics; repaglinide; T2DM
资金
- Ministry of Science and Technology [2011CB504001]
- NSFC [81322010]
- Excellent Young Medical Expert of Shanghai [XYQ2011041]
- Shanghai Talent Development Grant [2012041]
- National Young Top Talent Supporting Program
Glinides, including repaglinide, nateglinide and mitiglinide, are a type of fasting insulin secretagogue that could help to mimic early-phase insulin release, thus providing improved control of the postprandial glucose levels. Glinides stimulate insulin secretion by inhibiting ATP-sensitive potassium channels in the pancreatic beta-cell membrane. Although glinides have been widely used clinically and display excellent safety and efficacy, the response to glinides varies among individuals, which is partially due to genetic factors involved in drug absorption, distribution, metabolism and targeting. Several pharmacogenomic studies have demonstrated that variants of genes involved in the pharmacokinetics or pharmacodynamics of glinides are associated with the drug response. Polymorphisms of genes involved in drug metabolism, such as CYP2C9, CYP2C8 and SLCO1B1, may influence the efficacy of glinides and the incidence of adverse effects. In addition, Type 2 diabetes mellitus susceptibility genes, such as KCNQ1, PAX4 and BETA2, also influence the efficacy of glinides. In this article, we review and discuss current pharmacogenomics researches on glinides, and hopefully provide useful data and proof for clinical application.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据